Ratings United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq 21:00:00 19/07/2024 BST 5-day change 1st Jan Change
329.2 USD +0.15% Intraday chart for United Therapeutics Corporation +2.42% +49.69%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • With an enterprise value anticipated at 4.5 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
+49.69% 14.6B
B+
+21.81% 46.43B
B-
+43.45% 41.24B
A
-2.94% 40.92B
B
+24.25% 30.08B
B
-6.75% 27.85B
C
+16.47% 27.26B
B-
+37.44% 13.02B
C+
-2.20% 11.89B
B+
-7.68% 11.24B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. Ratings United Therapeutics Corporation